Breaking News Instant updates and real-time market news.

IRWD

Ironwood

$15.88

0.48 (3.12%)

07:32
10/03/16
10/03
07:32
10/03/16
07:32

Ironwood announces U.S. availability of Zurampic 200mg tablets

Ironwood Pharmaceuticals announced that ZURAMPIC is now available in pharmacies throughout the United States. ZURAMPIC is approved as a once-daily oral tablet to be taken in combination with a xanthine oxidase inhibitor for the treatment of hyperuricemia - high serum uric acid levels in the blood - associated with gout in patients who have not achieved target sUA levels with an XOI alone. ZURAMPIC is not recommended for the treatment of asymptomatic hyperuricemia and should not be used as monotherapy. The safety and efficacy of ZURAMPIC were established in three Phase III, multicenter, randomized, double-blind, 12-month, placebo-controlled clinical studies in adult patients with hyperuricemia and gout. In two of the trials, ZURAMPIC was studied in combination with allopurinol and in a third trial was studied in combination with febuxostat. Most common adverse reactions with ZURAMPIC in the clinical trials were headache, influenza, blood creatinine increased, and gastroesophageal reflux disease.

  • 06

    Nov

IRWD Ironwood
$15.88

0.48 (3.12%)

04/06/16
04/06/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. CRH (CRH) upgraded to Overweight at JPMorgan by analyst Elodie Rall, who views the valuation as attractive and sees limited risk to estimates. 2. Ironwood (IRWD) upgraded to Outperform at Cowen citing the company's pipeline and ex-U.S. royalties as well as U.S. co-marketing agreements leaving room for growth. 3. Owens-Illinois (OI) upgraded to Buy at Citi with analyst Anthony Pettinari citing valuation and a low bar set by management for 2016. 4. Pennsylvania REIT (PEI) upgraded to Outperform at Boenning & Scattergood by analyst Floris van Dijkum, who believes Pennsylvania REIT's discounted valuation is unwarranted given significant acceleration in 2018 NOI growth. van Dijkum expects the company to continue to reduce leverage by selling other non-core assets and make development progress on the Fashion Outlets of Philadelphia. 5. Cisco (CSCO) upgraded to Neutral at JPMorgan with analyst Rod Hall saying the company's 3.8% dividend yield is "compelling in the midst of current market volatility." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/26/16
JPMS
04/26/16
NO CHANGE
JPMS
Ironwood Linzess safety concerns overblown, says JPMorgan
04/26/16
COWN
04/26/16
NO CHANGE
COWN
Outperform
Ironwood short report does not discuss any new information, says Cowen
Cowen analyst Boris Peaker,commented on the short report on Ironwood (IRWD) issued by Phase Five Research and said it doesn't appear to discuss any new data. Peaker said the analysis ignores the co-morbidities of patients that are on Linzess, which has been in 2M patients, many with significant other illnesses and on multiple other background therapies. Additionally, the report overlooked the acquisition of Zurampic today from AstraZeneca (AZN) that was favorably structured with a $100M upfront payment to Ironwood, the analyst said. Peaker said feedback on Linzess from consultants at Cowen's Healthcare Conference was positive and reiterates his Outperform rating.
04/27/16
UBSW
04/27/16
NO CHANGE
Target $8
UBSW
Sell
Ironwood had no new safety concerns with Linzess, says UBS
UBS said the FDA had no new safety concerns and there were no regulatory actions required for Ironwood's Linzess drug. The firm expects the noise from yesterday's short report, which suggested the FDA had issues with Linzess, to subside as the safety concerns pointed to were not justified. UBS acknowledges they have not given much credit for the company's pipeline, but they prefer to stay on the sidelines and take a "wait and see" attitude. UBS maintained its Sell rating and $8 price target on Ironwood shares.

TODAY'S FREE FLY STORIES

TREX

Trex Company

$69.81

-0.76 (-1.08%)

07:03
02/21/17
02/21
07:03
02/21/17
07:03
Hot Stocks
Trex Company board approves new 2.96M share repurchase program »

The Company's Board…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 23

    Feb

TREX

Trex Company

$69.81

-0.76 (-1.08%)

07:03
02/21/17
02/21
07:03
02/21/17
07:03
Earnings
Trex Company reports Q4 EPS 43c, consensus 41c »

Reports Q4 revenue $95M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 23

    Feb

XCRA

Xcerra

$8.30

0.13 (1.59%)

07:02
02/21/17
02/21
07:02
02/21/17
07:02
Earnings
Xcerra reports Q2 non-GAAP EPS 6c, consensus (2c) »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SIX

Six Flags

$61.65

-0.14 (-0.23%)

07:01
02/21/17
02/21
07:01
02/21/17
07:01
Hot Stocks
Six Flags signs agreement to build Six Flags-branded parks at second China site »

Six Flags Entertainment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

INOV

Inovalon

$11.30

-0.45 (-3.83%)

07:01
02/21/17
02/21
07:01
02/21/17
07:01
Recommendations
Inovalon analyst commentary  »

Piper sees lawsuit as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

SRPT

Sarepta

$28.28

0.31 (1.11%)

07:00
02/21/17
02/21
07:00
02/21/17
07:00
Hot Stocks
Sarepta agrees to sale of priority review voucher for $125M »

Sarepta Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 28

    Feb

SEAS

SeaWorld

$19.21

-0.03 (-0.16%)

07:00
02/21/17
02/21
07:00
02/21/17
07:00
Earnings
Breaking Earnings news story on SeaWorld »

SeaWorld reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

TVPT

Travelport

$14.14

-0.06 (-0.42%)

06:58
02/21/17
02/21
06:58
02/21/17
06:58
Earnings
Travelport reports Q4 adjusted EPS 23c, consensus 20c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 01

    Mar

MDT

Medtronic

$78.88

0.89 (1.14%)

06:58
02/21/17
02/21
06:58
02/21/17
06:58
Earnings
Medtronic reports Q3 EPS $1.12, consensus $1.11 »

Reports Q3 revenue $7.3B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 22

    Feb

  • 22

    Feb

  • 27

    Feb

  • 27

    Feb

  • 07

    Mar

  • 17

    Mar

  • 21

    Mar

REXR

Rexford Industrial

$22.92

0.24 (1.06%)

06:57
02/21/17
02/21
06:57
02/21/17
06:57
Hot Stocks
Rexford Industrial acquires industrial property in Los Angeles for $17.1M »

Rexford Industrial Realty…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOXO

Loxo Oncology

$41.74

0.36 (0.87%)

06:56
02/21/17
02/21
06:56
02/21/17
06:56
Hot Stocks
Loxo Oncology completes enrollment for larotrectinib NDA »

Loxo Oncology announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$30.37

-0.08 (-0.26%)

06:56
02/21/17
02/21
06:56
02/21/17
06:56
Periodicals
GE succession plan near top of investors' minds, WSJ says »

General Electric CEO Jeff…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 26

    Apr

JELD

JELD-WEN Holding

$29.48

0.48 (1.66%)

06:56
02/21/17
02/21
06:56
02/21/17
06:56
Initiation
JELD-WEN Holding initiated  »

JELD-WEN Holding…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRVN

Trevena

$7.13

0.1 (1.42%)

06:55
02/21/17
02/21
06:55
02/21/17
06:55
Hot Stocks
Breaking Hot Stocks news story on Trevena »

Trevena trading halted,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 21

    Mar

TIF

Tiffany

$86.18

3.17 (3.82%)

06:54
02/21/17
02/21
06:54
02/21/17
06:54
Hot Stocks
Tiffany, JANA Partners announce agreement to appoint 3 new independent directors »

Tiffany and JANA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENBL

Enable Midstream

$16.73

0.11 (0.66%)

06:54
02/21/17
02/21
06:54
02/21/17
06:54
Hot Stocks
Breaking Hot Stocks news story on Enable Midstream »

Enable Midstream…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

ENBL

Enable Midstream

$16.73

0.11 (0.66%)

06:53
02/21/17
02/21
06:53
02/21/17
06:53
Earnings
Enable Midstream reports Q4 EPS 14c, consensus 18c »

Reports Q4 revenue $614M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

WLK

Westlake Chemical

$61.66

-0.99 (-1.58%)

06:51
02/21/17
02/21
06:51
02/21/17
06:51
Earnings
Westlake Chemical reports Q4 EPS 76c with items, consensus 80c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

JNCE

Jounce Therapeutics

$19.90

0.24 (1.22%)

06:51
02/21/17
02/21
06:51
02/21/17
06:51
Initiation
Jounce Therapeutics initiated  »

Jounce Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JELD

JELD-WEN Holding

$29.48

0.48 (1.66%)

06:50
02/21/17
02/21
06:50
02/21/17
06:50
Initiation
JELD-WEN Holding initiated  »

JELD-WEN Holding…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EDR

EdR

$40.69

-0.06 (-0.15%)

06:48
02/21/17
02/21
06:48
02/21/17
06:48
Earnings
EdR reaffirms FY17 EPS view 66c-76c, consensus 63c »

Sees FY17 core FFO per…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

HURN

Huron

$42.60

-4 (-8.58%)

06:48
02/21/17
02/21
06:48
02/21/17
06:48
Downgrade
Huron rating change  »

Huron downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 28

    Feb

EDR

EdR

$40.69

-0.06 (-0.15%)

06:47
02/21/17
02/21
06:47
02/21/17
06:47
Earnings
EdR reports Q4 EPS 19c, consensus 23c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

MCO

Moody's

$112.90

2.68 (2.43%)

06:45
02/21/17
02/21
06:45
02/21/17
06:45
Downgrade
Moody's rating change  »

Moody's downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 02

    Mar

  • 05

    Mar

RIC

Richmont Mines

$9.30

-0.2 (-2.11%)

06:45
02/21/17
02/21
06:45
02/21/17
06:45
Earnings
Richmont Mines reports Q4 EPS 1c, consensus 4c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.